| 361.1254 0.575 (0.16%) | 06-30 09:32 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 423.13 | 1-year : | 494.21 |
| Resists | First : | 362.26 | Second : | 423.13 |
| Pivot price | 348.65  |
|||
| Supports | First : | 337.56 | Second : | 322.29 |
| MAs | MA(5) : | 354.02 |
MA(20) : | 346.02 |
| MA(100) : | 350.09 |
MA(250) : | 321.22 |
|
| MACD | MACD : | 4.5 |
Signal : | 3.1 |
| %K %D | K(14,3) : | 84.9 |
D(3) : | 79.5 |
| RSI | RSI(14): 63.6 |
|||
| 52-week | High : | 388.35 | Low : | 264.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AMGN ] has closed below upper band by 5.5%. Bollinger Bands are 8.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 362.17 - 363.24 | 363.24 - 364.44 |
| Low: | 355.16 - 356.49 | 356.49 - 357.98 |
| Close: | 358.22 - 360.21 | 360.21 - 362.45 |
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Tue, 30 Jun 2026
Pathway Financial Advisers LLC Sells 5,382 Shares of Amgen Inc. $AMGN - MarketBeat
Tue, 30 Jun 2026
Forum Financial Management LP Sells 2,792 Shares of Amgen Inc. $AMGN - MarketBeat
Mon, 29 Jun 2026
Matrix Asset Advisors Inc. NY Sells 3,739 Shares of Amgen Inc. $AMGN - MarketBeat
Mon, 29 Jun 2026
Amgen Inc. $AMGN Holdings Lifted by Fort Washington Investment Advisors Inc. OH - MarketBeat
Sun, 28 Jun 2026
Nicholas Wealth LLC. Takes $1.16 Million Position in Amgen Inc. $AMGN - MarketBeat
Sat, 27 Jun 2026
Price to book forward of Amgen Inc. – NASDAQ:AMGN - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 540 (M) |
| Shares Float | 538 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 85.2 (%) |
| Shares Short | 12,200 (K) |
| Shares Short P.Month | 12,290 (K) |
| EPS | 14.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.03 |
| Profit Margin | 20.9 % |
| Operating Margin | 33.7 % |
| Return on Assets (ttm) | 8.3 % |
| Return on Equity (ttm) | 101.3 % |
| Qtrly Rev. Growth | 5.8 % |
| Gross Profit (p.s.) | 49.26 |
| Sales Per Share | 68.96 |
| EBITDA (p.s.) | 31.35 |
| Qtrly Earnings Growth | 4.4 % |
| Operating Cash Flow | 10,760 (M) |
| Levered Free Cash Flow | 7,440 (M) |
| PE Ratio | 25.09 |
| PEG Ratio | 1.9 |
| Price to Book value | 21.17 |
| Price to Sales | 5.22 |
| Price to Cash Flow | 18.08 |
| Dividend | 2.51 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|